Impax Settles With Abbott, Fournier to Sell Generic TriLipix

Impax Laboratories Inc. (IPXL) said it settled patent litigation with Abbott Laboratories (ABT) and its Fournier Laboratories Ireland Ltd. unit, permitting Impax to sell a generic version of the cholesterol drug TriLipix as early as 2013.

Impax, based in Hayward, California, may sell delayed- release capsules of TriLipix starting July 15, 2013, “under certain circumstances in the settlement agreement” that weren’t spelled out in a regulatory filing today. Otherwise, Impax may offer generic versions in 45-milligram or 135-milligram doses on Jan. 1, 2014, the filing said.

TriLipix reduces cholesterol and fatty acids called triglycerides in the blood. The drug, whose chemical name is choline fenofibrate, is a delayed-release version of Abbott’s TriCor medicine. Sales of Trilipix and TriCor were $963 million in the U.S. in the first nine months of the year, Abbott said in an earnings statement yesterday.

The agreement “allows Abbott to obtain certainty for our product and avoid costly litigation around our patent,” said Scott Stoffel, a spokesman for Abbott Park, Illinois-based Abbott.

Teva Pharmaceutical Industries Ltd. (TEVA), the world’s biggest generic-drug maker, plans to begin selling a generic version of TriCor in July under an earlier lawsuit settlement with Abbott.

The case is Abbott Laboratories v. Impax Laboratories, 10- cv-1322, U.S. District Court, District of New Jersey (Newark).

To contact the reporters on this story: David Voreacos in Newark at; Susan Decker in Washington at

To contact the editors responsible for this story: Michael Hytha at; Michael Shepard at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.